ABLI Stock Overview
Abliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Abliva AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.16 |
| 52 Week High | kr0.32 |
| 52 Week Low | kr0.14 |
| Beta | 1.06 |
| 1 Month Change | 7.24% |
| 3 Month Change | -31.91% |
| 1 Year Change | -30.89% |
| 3 Year Change | -78.51% |
| 5 Year Change | -87.44% |
| Change since IPO | -97.54% |
Recent News & Updates
Recent updates
Abliva (STO:ABLI) Is In A Strong Position To Grow Its Business
Dec 18
Here's Why We're A Bit Worried About Abliva's (STO:ABLI) Cash Burn Situation
Aug 24Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?
Aug 21We're Keeping An Eye On Abliva's (STO:ABLI) Cash Burn Rate
Oct 13Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?
Mar 22How Much Is Abliva AB (publ) (STO:ABLI) Paying Its CEO?
Dec 06Shareholder Returns
| ABLI | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -2.1% | -0.06% | 0.9% |
| 1Y | -30.9% | -5.3% | 10.3% |
Return vs Industry: ABLI underperformed the Swedish Biotechs industry which returned -4.3% over the past year.
Return vs Market: ABLI underperformed the Swedish Market which returned 10.7% over the past year.
Price Volatility
| ABLI volatility | |
|---|---|
| ABLI Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: ABLI's share price has been volatile over the past 3 months.
Volatility Over Time: ABLI's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 8 | Ellen Donnelly | abliva.com |
Abliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children’s Hospital of Philadelphia, and Oroboros Instruments.
Abliva AB (publ) Fundamentals Summary
| ABLI fundamental statistics | |
|---|---|
| Market cap | kr215.10m |
| Earnings (TTM) | -kr95.51m |
| Revenue (TTM) | kr137.00k |
1,570x
P/S Ratio-2.3x
P/E RatioIs ABLI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABLI income statement (TTM) | |
|---|---|
| Revenue | kr137.00k |
| Cost of Revenue | kr68.82m |
| Gross Profit | -kr68.68m |
| Other Expenses | kr26.83m |
| Earnings | -kr95.51m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 23, 2024
| Earnings per share (EPS) | -0.071 |
| Gross Margin | -50,132.85% |
| Net Profit Margin | -69,714.60% |
| Debt/Equity Ratio | 0% |
How did ABLI perform over the long term?
See historical performance and comparison